Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ: YMAB )

4.100 -0.030 (-0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product... 
Via Benzinga
Lost Money in Y-mAbs Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful
Via Benzinga
Where Y-mAbs Therapeutics Stands With Analysts
Within the last quarter, Y-mAbs Therapeutics (NASDAQ:YMAB) has observed the following analyst ratings: 
Via Benzinga
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – YMAB
From The Rosen Law Firm, P.A.
Via Business Wire
S&P 500 Down 0.5%; Crude Oil Falls Sharply
U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping around 0.5% on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day Session
Gainers 1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 96 stocks hit new 52-week lows. 
Via Benzinga
Nasdaq Down Over 100 Points; Chicago PMI Drops Further
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
US Stocks Start Week On Lower Note; Dow Dips Over 200 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 200 points on Monday. 
Via Benzinga
Grainger To Surge Over 11%? Plus This Analyst Predicts $230 For Caterpillar
UBS raised the price target on Caterpillar Inc. (NYSE: CAT) from $225 to $230. Caterpillar shares fell 1.1% to $216.85 in pre-market trading. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers PLx Pharma (NASDAQ:PLXP) stock increased by 15.5% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $20.3 million. 
Via Benzinga
TuSimple, Y-mAbs Therapeutics And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket
Gainers Selina Hospitality PLC (NASDAQ: SLNA) rose 31.9% to $19.90 in pre-market trading after dipping around 63% on Friday. 
Via Benzinga
FDA's AdComm Gives Thumbs Down To Pediatric Cancer Therapy
FDA's Oncologic Drugs Advisory Committee (ODAC) raised concerns regarding the efficacy of Y-mAbs Therapeutics Inc's (NASDAQ: YMAB) potential pediatric neuroblastoma treatment, omburtamab. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process... 
Via Benzinga
Lost Money in Y-mAbs Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Advisory Committee Meeting Scheduled For October 28, 2022 To Review Y-mAbs' Refiling For Omburtamab
The Oncologic Drugs Advisory Committee (ODAC) of the U.S. 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.